<?xml version="1.0" encoding="UTF-8"?>
<p>clinical stages with the corresponding recommended prescription.
 <sup>[
  <xref rid="R20" ref-type="bibr">20</xref>]
 </sup> Over 85% of confirmed cases involved CM use nationally (Wuhan over 67%)
 <sup>[
  <xref rid="R21" ref-type="bibr">21</xref>]
 </sup> and the first CM-oriented designated Module Hospital in Wuhan operated since 14 February 2020.
 <sup>[
  <xref rid="R22" ref-type="bibr">22</xref>]
 </sup> The clinical evidence of CM on COVID-19 is far from conclusive, but may be a good additional candidate at least for trial treatment considering the limited options available for COVID-19.
 <sup>[
  <xref rid="R18" ref-type="bibr">18</xref>]
 </sup> Early reported benefits of CM included symptomatic relief, shortening fever duration, reverting radiological changes, and shortening hospital stay.
 <sup>[
  <xref rid="R23" ref-type="bibr">23</xref>,
  <xref rid="R24" ref-type="bibr">24</xref>]
 </sup>
</p>
